Counterfeit Antiepileptic Drugs Threaten Community Services in Guinea-Bissau and Nigeria
Willem M Otte,Eric van Diessen,Pieter van Eijsden,Frank van der Maas,Philip N Patsalos,Paul N Newton,Inácio C Alvarenga,Kees P Braun,Josemir W Sander
DOI: https://doi.org/10.1016/s1474-4422(15)00255-0
IF: 59.935
2015-01-01
The Lancet Neurology
Abstract:Falsified drugs are a serious, yet vastly underreported, health-care hazard.1Degardin K Roggo Y Margot P Understanding and fighting the medicine counterfeit market.J Pharm Biomed Anal. 2014; 87: 167-175Crossref PubMed Scopus (130) Google Scholar Despite stringent regulations, counterfeit medications are becoming an increasing threat in low-income and lower-middle-income countries. Production of falsified drugs remains financially rewarding and largely risk-free because of inadequate law enforcement.1Degardin K Roggo Y Margot P Understanding and fighting the medicine counterfeit market.J Pharm Biomed Anal. 2014; 87: 167-175Crossref PubMed Scopus (130) Google Scholar We want to bring to the attention of the neurological community that promising efforts to address the huge epilepsy treatment gap in rural sub-Saharan Africa are being undermined by counterfeit antiepileptic drugs (AEDs). In lower-middle-income countries, more than 60% of people with epilepsy do not have access to AEDs or are inadequately treated.2Meinardi H Scott RA Reis R Sander JW The treatment gap in epilepsy: the current situation and ways forward.Epilepsia. 2001; 42: 136-149Crossref PubMed Scopus (300) Google Scholar Community-based epilepsy care programmes improve access to epilepsy treatment in these settings.3Wang WZ Wu JZ Ma GY et al.Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China.Lancet Neurol. 2006; 5: 46-52Summary Full Text Full Text PDF PubMed Scopus (108) Google Scholar WHO specifically advocates the use of community-based rehabilitation services based on local resources and personnel to improve the social integration of people living with a disability, including those with epilepsy.4Khasnabis C Motsch KH Community-based rehabilitation: CBR guidelines. World Health Organization, Geneva2010Google Scholar Between May and July 2013, a new phenobarbital formulation was used in a community-based rehabilitation service in South Guinea-Bissau to treat people with epilepsy. In June 2013, community workers reported breakthrough seizures in several patients and, by July, 74 (63%) of 117 patients had reported recurrence or increased frequency of seizures. Two people died, possibly as a result of seizures. Similar events were seen between June and August 2014 in Izzi, Ebonyi State, Nigeria, when the local community-based rehabilitation service switched phenobarbital supplier and started using a new brand of 30 mg tablets. During treatment with this new phenobarbital, 105 (88%) of 120 patients had a relapse or much higher seizure frequencies than before the switch. At both locations, the drugs were suspected to be responsible for the recrudescence of seizures. Batches were collected and independently analysed in a blinded fashion in two laboratories. The phenobarbital concentrations in tablets from the two suspect brands were either not detectable or extremely low (0·8–1·5%). The tablets from the Guinea-Bissau batch were brittle and varied substantially in weight. We have been unable to track either the manufacturers or the distribution sources for both new brands as their contact details were misleading or not specific enough, suggesting—together with the chemical analysis results—that the drug was falsified. The community-based rehabilitation services immediately banned the use of the falsified phenobarbital and reported the problem to non-governmental health-care organisations and WHO. Counterfeit AEDs had not been previously reported, nor are they a category in the Medicines Quality Database. Falsification of drugs is a serious crime, potentially even more damaging than the falsification of non-medical products.1Degardin K Roggo Y Margot P Understanding and fighting the medicine counterfeit market.J Pharm Biomed Anal. 2014; 87: 167-175Crossref PubMed Scopus (130) Google Scholar Counterfeit AEDs are detrimental because, first, withdrawal symptoms can be severe; second, sudden absence of efficiency could lead to a loss of confidence in the health-care system and might reduce access to treatment; and third, sudden loss of seizure control and consequent unexpected recurrence of seizures can be life-threatening. Community-based epilepsy services that rely on local personnel, resources, and procurement of AEDs are effective in bridging the epilepsy treatment gap in lower-middle-income countries. A sustainable supply of high quality and controlled AEDs is essential for these community-based epilepsy services. We believe that this counterfeit drug problem is very likely to affect other lower-middle-income countries that rely on community-based services for drug supply. Inexpensive generic drugs targeting epilepsy are therefore prone to falsification, and AEDs should be included in the Medicines Quality Database. Enhanced monitoring of AEDs quality is essential. In the setting of community-based rehabilitation services in Africa, we advise that, if a change of the frequency of seizures occurs, a key first step must be to investigate the quality of the AEDs administered. WMO and EvD contributed equally. JWS has received personal fees from GlaxoSmithKline, Eisai, UCB, Lundbeck, and Teva. He is based at the UCLH/UCL Comprehensive Bio-Medical Research Centre, which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. He is member of the Editorial Board of the Lancet Neurology. All other authors declare no competing interests.